Cargando…

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study

To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falcon-Neyra, Lola, Palladino, Claudia, Navarro Gómez, María Luisa, Soler-Palacín, Pere, González-Tomé, María Isabel, De Ory, Santiago J., Frick, Marie Antoinette, Fortuny, Clàudia, Noguera-Julian, Antoni, Moreno, Elena Bermúdez, Santos, Juan Luis, Olbrich, Peter, López-Cortés, Luis F., Briz, Verónica, Neth, Olaf
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2016
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4998448/ https://www.ncbi.nlm.nih.gov/pubmed/27310962 http://dx.doi.org/10.1097/MD.0000000000003842

Ejemplares similares

New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013
por: Jiménez de Ory, Santiago, et al.
Publicado: (2017)

Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIV
por: Rolle, Charlotte-Paige, et al.
Publicado: (2021)

Triple-combination rilpivirine, emtricitabine, and tenofovir (Complera™/Eviplera™) in the treatment of HIV infection
por: Bernardini, Claudia, et al.
Publicado: (2013)

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study
por: Troya, Jesús, et al.
Publicado: (2022)

Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia
por: Taramasso, Lucia, et al.
Publicado: (2019)

No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
por: Falcon-Neyra, Lola, et al.
Publicado: (2015)

Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood
por: Ruiz-Saez, Beatriz, et al.
Publicado: (2021)

Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen
por: Darnell, Julia, et al.
Publicado: (2021)

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
por: Wang, Huilian, et al.
Publicado: (2016)

Lack of clinically important PK interaction between coformulated ledipasvir/sofosbuvir and rilpivirine/emtricitabine/tenofovir alafenamide
por: Custodio, Joseph M., et al.
Publicado: (2017)

Adherence determination using urine-tenofovir point-of-care testing and pharmacy refill records: A cross-sectional study
por: Herbertson, Ebiere C., et al.
Publicado: (2023)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir
por: Gianotti, Nicola, et al.
Publicado: (2016)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

537 STaR: Single-Tablet Regimen Rilpivirine/Emtricitabine/Tenofovir DF has Similar Efficacy and is Well-Tolerated Compared to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Females at Week 96
por: Creticos, Catherine, et al.
Publicado: (2014)

Combination therapies, effectiveness, and adherence in patients with HIV infection: clinical utility of a single tablet of emtricitabine, rilpivirine, and tenofovir
por: Wainberg, Mark A
Publicado: (2013)

Simultaneous Spectrophotometric Method for Determination of Emtricitabine and Tenofovir Disoproxil Fumarate in Three-Component Tablet Formulation Containing Rilpivirine Hydrochloride
por: Venkatesan, S., et al.
Publicado: (2014)

Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy
por: Cozzi-Lepri, Alessandro, et al.
Publicado: (2014)

Review of tenofovir-emtricitabine
por: Masho, Saba Woldemichael, et al.
Publicado: (2007)

Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients
por: Gianotti, Nicola, et al.
Publicado: (2017)

Spatial Distribution Profiles of Emtricitabine, Tenofovir, Efavirenz, and Rilpivirine in Murine Tissues Following In Vivo Dosing Correlate with Their Safety Profiles in Humans
por: Seneviratne, Herana Kamal, et al.
Publicado: (2020)

Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
por: Dravid, Ameet, et al.
Publicado: (2022)

New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir
por: Patel, Nimish, et al.
Publicado: (2012)

Coformulated bictegravir, emtricitabine, tenofovir alafenamide after initial treatment with bictegravir or dolutegravir and emtricitabine/tenofovir alafenamide
por: Sax, Paul E., et al.
Publicado: (2018)

Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up
por: Charpentier, Charlotte, et al.
Publicado: (2015)

Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms
por: Venkatesan, S., et al.
Publicado: (2014)

Eosinophilic Colitis Associated with Emtricitabine/Tenofovir
por: Lozier, Matthew R, et al.
Publicado: (2018)

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy
por: Gianotti, Nicola, et al.
Publicado: (2015)

538 A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients
por: Monczor, Ana, et al.
Publicado: (2014)

Prospective etiological investigation of community-acquired pulmonary infections in hospitalized people living with HIV
por: Figueiredo-Mello, Claudia, et al.
Publicado: (2017)

Oral microbiome in HIV-associated periodontitis
por: Noguera-Julian, Marc, et al.
Publicado: (2017)

Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid
por: Decloedt, Eric H., et al.
Publicado: (2021)

Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries
por: Tierrablanca, Luis Enrique, et al.
Publicado: (2018)

Escalating and sustained immunovirological dissociation among antiretroviral drug-experienced perinatally human immunodeficiency virus-1-infected children and adolescents living in the Central African Republic: A STROBE-compliant study
por: Mossoro-Kpinde, Christian Diamant, et al.
Publicado: (2020)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Does Once-Daily Raltegravir Have Any Role in the Antiretroviral Treatment?
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2015)

Cardiovascular disease and prevention among people living with HIV in South Florida
por: Pyarali, Fahim, et al.
Publicado: (2021)

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure
por: Avendaño-Ortiz, José, et al.
Publicado: (2020)

Reproductive history before and after HIV diagnosis: A cross-sectional study in HIV-positive women in Spain
por: Hernando, Victoria, et al.
Publicado: (2017)

Loss to follow-up and opportunities for reengagement in HIV care in rural Mozambique: A prospective cohort study
por: Fuente-Soro, Laura, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9jinm0surcqi9pq64rjfk3npln